Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 72
Summary
- Conditions
- Idiopathic Pulmonary Fibrosis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 ?JAK2 and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The study is a randomised,multicentre,double-blind,placebo-controlled,study.
This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 ?JAK2 and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The study is a randomised,multicentre,double-blind,placebo-controlled,study.
Tracking Information
- NCT #
- NCT04312594
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Xu Zuo Jun Peking Union Medical College Hospital
Get Well Soon